Greenwich LifeSciences (GLSI) Operating Expenses (2019 - 2025)

Greenwich LifeSciences' Operating Expenses history runs 7 years deep, the most recent figure standing at $9.2 million for Q4 2025.

• Quarterly Operating Expenses fell 5.5% year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.4 million (up 10.27% YoY) and the FY2025 annual result came in at $19.4 million, up 10.27% from the prior year.
• Operating Expenses was $9.2 million for Q4 2025 at Greenwich LifeSciences, up from $3.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $9.7 million in Q4 2024 and bottomed at $600606.0 in Q1 2021.
• A 5-year average of $3.0 million and a median of $2.5 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2021 — Operating Expenses jumped 258.05% — and 2025, when it slipped 5.5%.
• Greenwich LifeSciences' Operating Expenses stood at $2.4 million in 2021, then increased by 21.77% to $2.9 million in 2022, then dropped by 2.03% to $2.8 million in 2023, then surged by 242.36% to $9.7 million in 2024, then slipped by 5.5% to $9.2 million in 2025.
• Business Quant data shows GLSI's Operating Expenses at $9.2 million in Q4 2025, $3.7 million in Q3 2025, and $3.8 million in Q2 2025.